Micah Lieberman, the founder of ClinEco and CHI, recently shared his insights at the SCOPE (Summit for Clinical Ops Executives)...
Expansion of Approval for Medicine to Treat Eosinophilic Esophagitis Eosinophilic Esophagitis (EoE) is a chronic immune-mediated disorder that affects the...
The Food and Drug Administration (FDA) has recently approved the use of Dupixent (dupilumab) for children under 12 years old...
Aulos Bioscience, a leading biotechnology company, has recently announced the administration of the first dose to a patient in the...
Aulos Bioscience, a leading biotechnology company, has recently announced the administration of the first dose to a patient in the...
A Guide on Collaborating with a Clinical Trial Patient Recruitment Agency Clinical trials play a crucial role in advancing medical...
Understanding the Implications of Gilead’s Trodelvy Challenges and Elevation Oncology’s Unexpected Success In the world of oncology, the development and...
Understanding the Distinction: Screening versus Enrollment in Clinical Trials Clinical trials play a crucial role in advancing medical knowledge and...
The Journey of LMK Clinical Research, LLC: Achieving TMF Excellence in Biotech – TMF Corporate Education Chronicles In the fast-paced...
Strand Therapeutics, a leading biotechnology company specializing in developing innovative RNA-based therapies, has recently received approval from the Food and...
Understanding the Role of a Phase 1 Clinical Study Protocol Champion at BioPharma Services In the world of clinical research,...
Promising Results of CAR T-Cell Therapy in Early Phase Trial for Pancreatic and Gastric Cancers Pancreatic and gastric cancers are...
Title: FDA Warnings, Bryan Johnson’s NYT Feature, and MUSE Cell Trial: Key Developments in the Biotech Industry Introduction: The biotech...
Regenerative medicine is a rapidly evolving field that holds great promise for the treatment of various diseases and injuries. This...
The Food and Drug Administration (FDA) has recently approved a groundbreaking drug called Balversa (erdafitinib) for the treatment of FGFR3+...
